Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614736 | 0.88 | PREP (0.35) | PREPNR1H2 | |
| SCHEMBL30242481 | 0.87 | PREP (0.39) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL22032728 | 0.87 | PREP (0.39) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL30242513 | 0.87 | PREP (0.39) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL17049887 | 0.85 | PREP (0.42) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL18633742 | 0.81 | PREP (0.39) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL24337573 | 0.79 | USP2 (0.38) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL22072991 | 0.78 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL30242510 | 0.78 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL1486976 | 0.78 | PREP (0.43) | PREPNR1H2USP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-108349961-B | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | 西奈山伊坎医学院 | 2022-02-18 | — | — | CN | disclosed |
| WO-2021150700-A1 | N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021150697-A1 | N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-29 | — | — | WO | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-10-22 | — | — | US | disclosed |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180251444-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3347355-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | Icahn School of Medicine at Mount Sinai (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3331867-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | Icahn School of Medicine at Mount Sinai (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017044572-A1 | RING CONSTRAINED DIARYLAMINO SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044571-A1 | TRICYCLIC SULTAM SULFONAMIDES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251444-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | PREP 3969/4885NR1H2 2255/4885USP2 1052/4885 |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | PREP 3969/4885NR1H2 2255/4885USP2 1052/4885 |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | DDT, ODC1, CBR1 | PREP 3824/4885NR1H2 1240/4885USP2 3305/4885 |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | PREP 3969/4885NR1H2 2255/4885USP2 1052/4885 |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | PREP 3969/4885NR1H2 2255/4885USP2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.